Incyte has a collaboration agreement with Novartis ( NVS - Free Report ) for Jakafi. The approval of additional indications should generate incremental revenues. It has been raining good news for Incyte this week after a few setbacks earlier in the year. On Sep 21, the FDA approved the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis (AD). Ruxolitinib cream has been approved under the brand name Opzelura for the short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 12 years of age and older.